S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Inventiva Stock Price, News & Analysis (NASDAQ:IVA)

$4.32
+0.12 (+2.86%)
(As of 12/1/2023 ET)
Compare
Today's Range
$4.15
$4.39
50-Day Range
$3.62
$4.44
52-Week Range
$2.22
$6.82
Volume
4,124 shs
Average Volume
4,576 shs
Market Capitalization
$223.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.40

Inventiva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
279.6% Upside
$16.40 Price Target
Short Interest
Healthy
0.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.21) to ($2.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

407th out of 951 stocks

Pharmaceutical Preparations Industry

174th out of 431 stocks


IVA stock logo

About Inventiva Stock (NASDAQ:IVA)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Stock Price History

IVA Stock News Headlines

Brokerages Set Inventiva S.A. (NASDAQ:IVA) PT at $16.40
Analysts’ Top Healthcare Picks: Morphosys Ag (MOR), Abbott Labs (ABT)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Inventiva reports 9M results
Inventiva Share Price (IVA.PA)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Pre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…
Inventiva ADRs Rise 9% Following Licensing Deal
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
117
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$16.40
High Stock Price Target
$35.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+279.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.83 million
Book Value
$1.14 per share

Miscellaneous

Free Float
35,192,000
Market Cap
$223.56 million
Optionable
Not Optionable
Beta
0.92

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Frederic Cren (Age 57)
    Co-Founder, CEO & Chairman
    Comp: $550.18k
  • Dr. Pierre Broqua Ph.D. (Age 61)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $412.67k
  • Mr. Jean Volatier (Age 58)
    Chief Financial Officer
  • Alice Roudot-Ketelers Pharm.D.
    Chief Operating Officer
  • Mr. Eric Duranson L.L.M. (Age 49)
    General Counsel
  • Ms. Nathalie Harroy (Age 56)
    Head of Human Resources
  • Dr. Irena Konstantinova
    Head of Biology & Pharmacology
  • Dr. Michael Cooreman (Age 65)
    Chief Medical Officer
  • Mr. Jean-Paul Dutertre M.D.
    Head of Pharmacovigilance














IVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVA shares.
View IVA analyst ratings
or view top-rated stocks.

What is Inventiva's stock price target for 2024?

7 Wall Street analysts have issued 1-year price targets for Inventiva's shares. Their IVA share price targets range from $11.00 to $35.00. On average, they expect the company's share price to reach $16.40 in the next twelve months. This suggests a possible upside of 279.6% from the stock's current price.
View analysts price targets for IVA
or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2023?

Inventiva's stock was trading at $4.46 at the start of the year. Since then, IVA stock has decreased by 3.1% and is now trading at $4.32.
View the best growth stocks for 2023 here
.

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

Who are Inventiva's major shareholders?

Inventiva's stock is owned by many different retail and institutional investors. Top institutional shareholders include Commonwealth Equity Services LLC (0.05%).

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IVA) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -